These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 372653)

  • 41. [On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)].
    Desselberger U; Pressler K; Erdmann G
    Zentralbl Bakteriol Orig A; 1975 Jul; 232(2-3):160-77. PubMed ID: 1179878
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Reactivity and immunologic activity of polyvalent split influenza vaccine in children].
    Závadová H; Domorázková E; Skovránková J; Vodicková M; Ragac P; Vonka V
    Cesk Pediatr; 1990 Jun; 45(6):344-6. PubMed ID: 2289253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virus-induced enhancement of lymphocyte-mediated antibody-dependent cytotoxicity (ADCC) in vitro.
    Alsheikhly AR; Wåhlin B; Andersson T; Perlmann P
    J Immunol; 1984 Jun; 132(6):2760-6. PubMed ID: 6373918
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)].
    Kuwert EK; Werner J; Scheiermann N; Pledt T
    Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):155-74. PubMed ID: 506543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Complement sensitivity of neuraminidase-treated lymphoid cells.
    Ray PK; Gewurz H; Simmons RL
    Transplantation; 1971 Oct; 12(4):327-9. PubMed ID: 4107114
    [No Abstract]   [Full Text] [Related]  

  • 46. Interactions between neuraminidase-treated lymphocytes and liver cells.
    Kolb H; Kriese A; Kolb HA
    Adv Exp Med Biol; 1979; 114():219-22. PubMed ID: 463642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human lymphocyte antigen reactivity modified by neuraminidase.
    Grothaus EA; Flye MW; Yunis E; Amos DB
    Science; 1971 Aug; 173(3996):542-4. PubMed ID: 5564043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Letter: Naturally occurring human antibody to neuraminidase-treated human lymphocytes.
    Gray BN
    J Natl Cancer Inst; 1976 Feb; 56(2):211-2. PubMed ID: 56446
    [No Abstract]   [Full Text] [Related]  

  • 49. Possible mechanism of entrapment of neuraminidase-treated lymphocytes in the liver.
    Kolb H; Kriese A; Kolb-Bachofen V; Kolb HA
    Cell Immunol; 1978 Oct; 40(2):457-62. PubMed ID: 719764
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunological characteristics of neo-antigens on the cell surface after neuraminidase treatment.
    Johannsen R; Sedlacek HH; Seiler FR
    Adv Exp Med Biol; 1979; 114():223-7. PubMed ID: 463643
    [No Abstract]   [Full Text] [Related]  

  • 51. Naturally occurring human antibody to neuraminidase-treated human lymphocytes. Antibody levels in normal subjects, cancer patients, and subjects with immunodeficiency.
    Rogentine N
    J Natl Cancer Inst; 1975 Jun; 54(6):1307-11. PubMed ID: 1133848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A micromethod for lymphocyte treatment with neuraminidase: importance in the study of lymphocytotoxic antibodies].
    de Mouzon A; Ohayon E; Ducos J
    Rev Fr Transfus Immunohematol; 1977 Mar; 20(1):23-6. PubMed ID: 882789
    [No Abstract]   [Full Text] [Related]  

  • 53. Decreased levels of circulating lytic anti-T in the serum of patients with metastatic gastrointestinal cancer: a correlation with disease burden.
    Bray J; MacLean GD; Dusel FJ; McPherson TA
    Clin Exp Immunol; 1982 Jan; 47(1):176-82. PubMed ID: 7094422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells.
    Pfreundschuh M; Dörken B; Brandeis W; Hunstein W; Wernet P
    Cancer Immunol Immunother; 1983; 15(3):194-9. PubMed ID: 6193868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increase in titer of the naturally occurring human antibody to neuraminidase-treated lymphocytes after influenza.
    Rogentine GN; Doherty CM; Pincus SH
    J Immunol; 1977 Nov; 119(5):1652-4. PubMed ID: 915272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Lymphocytes HLA antigens expressivity after neuraminidase treatment (author's transl)].
    de Mouzon A; Ohayon E; Oksman-Domejean F; Ducos J
    Ann Immunol (Paris); 1976; 127(5):687-701. PubMed ID: 984732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro methods for assessment of antibody-mediated tumor immunity.
    Levy NL; Amos DB; Solovieff GV; dos Reis AP
    Natl Cancer Inst Monogr; 1972 Dec; 35():5-11. PubMed ID: 4349154
    [No Abstract]   [Full Text] [Related]  

  • 58. Detection and localization of a lectin on Actinomyces viscosus T14V by monoclonal antibodies.
    Cisar JO; Barsumian EL; Curl SH; Vatter AE; Sandberg AL; Siraganian RP
    J Immunol; 1981 Oct; 127(4):1318-22. PubMed ID: 6115881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of cytotoxic antibodies against neuraminidase-treated lymphocytes in man.
    Johannsen R; Sedlacek HH; Schmidtberger R; Schick HJ; Seiler FR
    J Natl Cancer Inst; 1979 Apr; 62(4):733-42. PubMed ID: 372653
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.